Juno Tells Fed. Circ. To Uphold Its $1.2B Patent Win Over Kite
Because Kite Pharma Inc. "brazenly chose" to infringe a cancer treatment patent with its Yescarta treatment, the Federal Circuit should not undo a lower court's $1.2 billion decision against it, Juno...To view the full article, register now.
Already a subscriber? Click here to view full article